0001607062-19-000346.txt : 20190820 0001607062-19-000346.hdr.sgml : 20190820 20190820124718 ACCESSION NUMBER: 0001607062-19-000346 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190820 DATE AS OF CHANGE: 20190820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iGambit, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-53862 FILM NUMBER: 191038509 BUSINESS ADDRESS: STREET 1: 1050 W JERICHO TURNPIKE STREET 2: SUITE A CITY: SMITHTOWN STATE: NY ZIP: 11788 BUSINESS PHONE: 631-670-6777 MAIL ADDRESS: STREET 1: 1050 W JERICHO TURNPIKE STREET 2: SUITE A CITY: SMITHTOWN STATE: NY ZIP: 11788 10-Q/A 1 igmb063019form10qa.htm FORM 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q/A

Amendment No. 1

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly period ended June 30, 2019

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from to

Commission file number 000-53862

iGambit Inc.

(Exact name of small business issuer as specified in its charter)

Delaware	11-3363609
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1050 W. Jericho Turnpike, Suite A
Smithtown, New York 11787
(Address of Principal Executive Offices) (Zip Code)

(631) 670-6777
(Issuer’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ☒

Emerging Growth Company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of August 19, 2019, the Registrant had 388,553,890 (not including 10 million shares held in treasury) shares of the Registrant’s $0.001 par value common stock outstanding.

iGambit Inc.

EXPLANATORY NOTE

The purpose of this amendment on Form 10-K to iGambit Inc.’s Annual Report for the period ended June 30, 2019, filed with the Securities and Exchange Commission on August 19, 2019, is solely to furnish Exhibit 101 to the Form 10Q in accordance with Rule 405 of Regulation S-T and to correct two 7typographical errors in Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations. No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, and does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosure made in the original Form 10-Q.

iGambit Inc.
Form 10-Q

		Page No.
Part I — Financial Information
Item 1.	Financial Statements:		4
	Condensed Consolidated Balance Sheets		4
	Condensed Consolidated Statements of Income		5
	Condensed Consolidated Statements of Changes in Stockholders’ Equity		6
	Condensed Consolidated Statements of Cash Flows		7
	Notes to Condensed Consolidated Financial Statements		8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		30
Item 4.	Controls and Procedures		30
Part II — Other Information
Item 1.	Legal Proceedings		31
Item 1A.	Risk Factors		31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		31
Item 3.	Defaults upon Senior Securities		31
Item 4.	Removed and Reserved		31
Item 5.	Other Information		31
Item 6.	Exhibits		31
Signature			32

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

IGAMBIT INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

		JUNE 30,			DECEMBER 31,
		2019			2018
ASSETS
Current assets
Cash	$	75,456		$	369
Accounts receivable		10,366			14,871
Inventory		26,988			27,073
Total current assets		112,810			42,313

Other assets
Property and equipment, net		1,623			2,118
Intangible assets, net		2,224,081			2,572,015
Deposits		300			2,020
	$	2,338,814		$	2,618,466

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses	$	657,563		$	480,270
Accrued interest on notes payable		18,630			32,265
Amounts due to related parties		128,476			145,367
Deferred revenue		2,617			9,192
Notes payable		445,593			52,500
Convertible notes payable, net		72,254			377,611
Derivative liability		—			288,242
Total current liabilities		1,325,133			1,385,447

Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares;issued and outstanding - 0 shares in 2019 and 2018, respectively		—			—
Common stock, $.001 par value; authorized - 800,000,000 shares;398,553,890 and 214,859,994 shares issued and 388,553,890 and 204,859,994 shares outstanding (net of treasury shares) as of June 30, 2019 and December 31, 2018, respectively		398,554			214,860
Additional paid-in capital		15,207,703			14,480,973
Accumulated deficit		(13,592,576	)		(12,462,814	)
		2,013,681			2,233,019
Less: Treasury stock; 10,000,000 shares, at cost		(1,000,000	)		(1,000,000	)
Total stockholders' equity		1,013,681			1,233,019
	$	2,338,814		$	2,618,466

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	THREE MONTHS						SIX MONTHS
	ENDED						ENDED
	JUNE 30,						JUNE 30,
	2019			2018			2019			2018
Sales	$	6,300		$	3,726		$	11,625		$	7,918
Cost of sales		8,087			7,894			16,294			15,824
Gross profit (loss)		(1,787	)		(4,168	)		(4,669	)		(7,906	)

Operating expenses
General and administrative expenses		198,953			310,873			389,217			545,137
Amortization		173,968			173,968			347,935			347,935
Total operating expenses		372,921			484,841			737,152			893,072

Loss from operations		(374,708	)		(489,009	)		(741,821	)		(900,978	)

Other income (expenses)
Change in fair value of derivative liability		152,107			(86,090	)		98,944			(204,191	)
Loss on extinguishment of debt		(256,698	)		(74,571	)		(262,566	)		(138,270	)
Interest expense		(91,066	)		(76,577	)		(224,319	)		(92,841	)
Total other income (expenses)		(195,657	)		(237,238	)		(387,941	)		(435,302	)

Net loss	$	(570,365	)	$	(726,247	)	$	(1,129,762	)	$	(1,336,280	)

Basic and fully diluted loss per common share:
Net loss per common share	$	(.00	)	$	(.01	)	$	(.00	)	$	(.01	)
Weighted average common shares outstanding - basic and fully diluted		380,608,478			127,632,070			333,669,806			124,456,325

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
SIX MONTHS ENDED JUNE 30, 2019 AND 2018


	Common stock
	Shares		Amount		Additional Paid-inCapital		Accumulated Deficit			Treasury Stock			Totals
Balances, December 31, 2017		126,196,571	$	126,196	$	12,891,348	$	(9,648,569	)	$	(1,000,000	)	$	2,368,975
Common stock issued for cash		750,000		750		14,250		—			—			15,000
Notes payable and accrued interest converted to common stock		5,344,180		5,345		342,758		—			—			348,103
Net loss								(610,033	)					(610,033	)
Balances, March 31, 2018		132,290,751	$	132,291	$	13,248,356	$	(10,258,602	)	$	(1,000,000	)	$	2,122,045
Common stock issued for cash		1,500,000		1,500		28,500		—			—			30,000
Notes payable and accrued interest converted to common stock		15,462,376		15,463		698,455		—			—			713,918
Common stock issued for services		3,000,000		3,000		85,800		—			—			88,800
Net loss								(1,336,280	)					(1,336,280	)
Balances, June 30, 2018		152,253,127	$	152,254	$	14,061,111	$	(11,594,882	)	$	(1,000,000	)	$	1,618,483

Balances, December 31, 2018		214,859,994	$	214,860	$	14,480,973	$	(12,462,814	)	$	(1,000,000	)	$	1,233,019
Compensation for vested stock options		—		—		1,025		—			—			1,025
Notes payable and accrued interest converted to common stock		146,727,525		146,727		402,081		—			—			548,808
Net loss								(559,397	)					(559,397	)
Balances, March 31, 2019		361,587,519	$	361,587	$	14,884,079	$	(13,022,211	)	$	(1,000,000	)	$	1,223,455
Notes payable and accrued interest converted to common stock		36,966,371		36,967		323,624		—			—			360,591
Net loss								(570,365	)					(570,365	)
Balances, June 30, 2019		398,553,890	$	398,554	$	15,207,703	$	(13,592,576	)	$	(1,000,000	)	$	1,013,681

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED JUNE 30,
(UNAUDITED)


		2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,129,762	)	$	(1,336,280	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		494			863
Amortization		347,935			347,935
Non cash interest expense		222,736			91,008
Stock-based compensation expense		1,025			88,800
Loss on extinguishment of debt		262,566			138,270
Change in fair value of derivative liability		(98,944	)		204,191
Changes in operating assets and liabilities:
Accounts receivable		4,505			5,128
Inventory		85			—
Prepaid expenses and other current assets		—			33,716
Deposits		1,720			—
Accounts payable and accrued expenses		177,293			(58,213	)
Deferred revenue		(6,575	)		(7,450	)
NET CASH USED IN OPERATING ACTIVITIES		(216,922	)		(492,032	)

CASH FLOWS FROM INVESTING ACTIVITIES:		—			—

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures		168,500			503,500
Repayments of convertible debentures		(257,693	)		—
Proceeds from sale of common stock		—			30,000
Proceeds from notes payable		393,093			—
Proceeds from related party loans		11,254			—
Repayments of related party loans		(23,145	)		—
NET CASH PROVIDED BY FINANCING ACTIVITIES		292,009			533,500

NET INCREASE IN CASH		75,087			41,468

CASH - BEGINNING OF PERIOD		369			9,449

CASH - END OF PERIOD	$	75,456		$	50,917

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	1,583		$	1,834

Non-cash investing and financing activities:
Debt discount related to derivative liability	$	222,500		$	224,249
Notes payable converted to common stock		326,189			257,000
Common stock issued in payment of accrued interest		19,868			15,466

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.

Notes to Condensed Consolidated Financial Statements

Six Months Ended June 30, 2019 and 2018

(Unaudited)

Note 1 - Organization and Basis of Presentation

The consolidated financial statements presented are those of iGambit Inc., (the “Company”) and its wholly-owned subsidiary, HealthDatix, Inc. (“HealthDatix. The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States.

Interim Financial Statements

The following (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2019.

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the six months ended June 30, 2019 and year ended December 31, 2018.

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the six months ended June 30, 2019 and 2018.

iGambit is a holding company and has no sources of revenue.

HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventory

Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation

Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures		5 - 7 years
Computer hardware		5 years
Computer software		3 years
Development equipment		5 years

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software		5 years
Technology license		5 years
Purchased in process R&D		Indefinite
Customer contracts		10 years

Long-Lived Assets

The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue

Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $2,617 and $9,192 as of June 30, 2019 and December 31, 2018, respectively.

Stock-Based Compensation

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Recent Accounting Pronouncements

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 3 – Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $13,592,576, and a working capital deficit of $1,212,323 at June 30, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Property and Equipment

Property and equipment are carried at cost and consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,341		8,846
	$	1,623	$	2,118

Depreciation expense of $494 and $863 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Note 5 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018		Life
Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		1,577,690		1,229,756
	$	2,224,081	$	2,572,015

Amortization expense of $347,935 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Note 6 - Earnings (Loss) Per Common Share

The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the six months ended June 30, 2019 and 2018 as the result would be anti-dilutive.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Stock options		20,250,000		8,463,000		20,250,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Total shares excluded from calculation		21,875,000		10,363,000		21,875,000		10,363,000

Note 7 – Stock Based Compensation

Options

In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan"). Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of June 30, 2019, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.

The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock. 8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date. There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.

Stock option activity during the six months ended June 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at June 30, 2018		8,463,000		$	0.07		0.07		6.91
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options expired		(250,000	)		0.05		—
Options outstanding at June 30, 2019		20,250,000		$	0.03	$	0.03		7.72

Options outstanding at June 30, 2019 consist of:

Date	Number		Number		Exercise		Expiration
Issued	Outstanding		Exercisable		Price		Date
March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
April 6, 2017		600,000		600,000	$	0.03		April 6, 2027
June 6, 2017		700,000		700,000	$	0.07		June 6, 2022
June 6, 2017		6,500,000		6,500,000	$	0.07		June 6, 2027
November 1, 2018		12,250,000		12,250,000	$	0.01		November 1, 2028
Total		20,250,000		20,250,000

Warrants

In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expired on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.

Warrant activity during the six months ended June 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at June 30, 2018		1,900,000		$	0.21	$	0.12		3.75
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at June 30, 2019		1,625,000		$	0.03	$	0.03		3.15

Warrants outstanding at June 30, 2019 consist of:

Date	Number		Number		Exercise		Expiration
Issued	Outstanding		Exercisable		Price		Date
January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
Total		1,625,000		1,625,000

Note 8 – Convertible Debt

Convertible Notes Payable

On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $240,000, convertible into shares of the Company’s common stock, and includes a back-ended note with principal of $120,000 that was funded on July 10, 2018. The back-ended Note, including accrued interest is due July 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted $71,732 of the principal balance and accrued interest of $5,366 to 48,693,873 shares of common stock. The principal balance of the note of $94,268, accrued interest of $7,417, and prepayment penalty of $5,000 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $60,000 and accrued interest of $4,342 to 35,446,300 shares of common stock.

On May 3, 2018, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35% applied to the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 130%. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $53,957 and accrued interest of $4,600 to 25,674,344 shares of common stock.

On June 25, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $38,000 and accrued interest of $2,120 to 14,859,260 shares of common stock.

On August 13, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due May 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $2,120 to 26,247,619 shares of common stock.

On September 17, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $33,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due June 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $1,320 to 31,762,500 shares of common stock.

On January 3, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,659, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On February 15, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due November 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,259, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On March 29, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due February 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $810, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On May 22, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $280, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 9) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated January 10, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated March 6, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated May 3, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated June 25, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated August 13, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated September 17, 2018 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $218,454 and $61,479 was recorded for the six months ended June 30, 2019 and 2018, respectively.

The Company issued convertible debentures in the amount of $75,000 to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the year. Interest expense on the convertible debentures of $3,699 was recorded for the six months ended June 30, 2019 and 2018, respectively.

Convertible notes payable at June 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018
Total face value of notes	$	75,000	$	478,957
Less: Discount		2,746		101,346
Balance	$	72,254	$	377,611

Note 9 – Derivative Liability

The Company has determined that the conversion feature embedded in the convertible notes described in Note 8 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception. The Company used the Binomial Option Pricing model to value the conversion features.

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

	June 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Note 10 – Notes Payable

On June 24, 2019, the Company entered into a secured promissory note with Clinigence Holdings, Inc. (“Clinigence”) for proceeds of $393,093, of which $293,093 was utilized to pay outstanding principal, accrued interest and penalties of certain convertible notes payable, and $100,000 was utilized for working capital. The note bears interest at a rate of 6% and is due upon the earlier of December 24, 2019 or the Merger Agreement (See note 16).

Notes payable at June 30, 2019 and December 31, 2018 consists of loans to HealthDatix from 3 individuals totaling $52,500. The loans do not bear interest and there are no specific terms for repayment.

Note 11 – Stock Transactions

Designation of Preferred Stock

On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company.

Common Stock Issued

On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share.

In connection with the convertible notes payable (see Note 8 above) the noteholders converted $326,189 of principal balance and $19,868 of accrued interest to 182,683,896 shares of common stock during the six months ended June 30, 2019. The stock issued was determined based on the terms of the convertible notes.

Note 12 - Income Taxes

A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

HealthDatix had sales to two customers which accounted for approximately 22% and 16%, respectively of HealthDatix’s total sales for the six months ended June 30, 2019. One customer accounted for approximately 96% of accounts receivable at June 30, 2019.

HealthDatix had sales to four customers which accounted for approximately 32%, 23%, 22%, and 10%, respectively of HealthDatix’s total sales for the six months ended June 30, 2018. One customer accounted for 100% of accounts receivable at June 30, 2018.

Cash

Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at June 30, 2019 and December 31, 2018, respectively.

Note 14 - Related Party Transactions

Amounts Due to Related Parties

Amounts due to related parties with balances of $128,476 and $145,367 at June 30, 2019 and December 31, 2018, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 – Commitments and Contingencies

Lease Commitment

The Company was obligated under an operating lease for its premises in Smithtown, New York that expired on May 31, 2019. The lease was not renewed and the officers of the Company are providing office space to the Company at no charge.

Rent expense of $15,262 and $14,235 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Employment Arrangements With Executive Officers

Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 – Subsequent Events

On August 9, 2019, the Company entered into a definitive merger agreement with Clinigence Holdings, Inc. pursuant to which the companies will combine in a stock-for-stock merger transaction. Pursuant to the merger agreement, iGambit shall issue newly-issued shares of common stock, on a fully-diluted pro rata basis, to the equity holders of Clinigence by means of a reverse triangular merger in which a wholly owned subsidiary of iGambit shall merge with and into Clinigence, with Clinigence continuing as the surviving corporation (the “Merger”). If the closing of the Merger occurs (the “Closing”), the former Clinigence equityholders shall own 85% of iGambit’s issued and outstanding common stock and the former iGambit equityholders shall own 15% of iGambit’s issued and outstanding common stock, in each case on a fully-diluted, as converted basis as of immediately prior to the Closing (including options, warrants and other rights to acquire equity securities of iGambit).

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

INTRODUCTION

Introduction

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our subsidiary HealthDatix™ Inc.

HealthDatix is a medical technology company that provides end to end Software-as-a-Service solutions, services and products via our HealthDatix Platform that manages, reports, and analyzes critical data, enabling healthcare and commercial organizations to deliver positive member outcomes.

HealthDatix Platform Products and Services

Health Risk Assessment (HRA)

Our Health Risk Assessment (HRA) solution is a standardized method of collecting health risk data from patients or employees that can be used by Wellness Clinics, Insurance Companies, Third Party Administrators (TPA’s) and/or self insured companies to identify the health risks of their employee or patient population. Our HRA solution can be tailored to deliver the HRA and a Preventive Plan for all beneficiaries and their dependents.

Target Market : Insurance Companies, TPA’s and/or self-insured companies.

Annual Wellness Visit (AWV)

Our Annual Wellness Visit (AWV) solution allows for a mass check of patients with CMS to determine if and when they are eligible for an initial or subsequent AWV and identifies eligibility for other preventive screenings. Our proprietary algorithm determines a patients’ qualification for preventive screenings, health and lifestyle risks and if they have 2 or more qualifying chronic conditions that make them eligible for CCM. The program creates a 5-10 year preventive plan for the patient and meets all of CMS audit requirements to bill for the services. The AWV provides a proactive approach to patient care and increases practice revenue by identifying and executing CMS recommended screenings for the patient to catch early disease states before they become chronic conditions

Target Market: Medicare Programs including ACO’s, Primary Care Offices, Chronic Care Management and Non-Medicare including Wellness Clinics, Insurance Companies, Medicare Advantage Plans (MAP)

BioDatix HealthBand

Our BioDatix Health Band requires our Remote Patient Monitoring (RPM) solution that speaks to our FDA cleared Electronic House Call system. The BioDatix Health Band passively collects heart rate, blood pressure, blood oxygen every 15 minutes. It calculates sleep and steps and sends to our BioDatix iOS/Android app and then to our RPM solution.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

BioDatix Remote Patient Monitoring

In addition to our BioDatix HealthBand, our RPM solution accepts data from multiple FDA approved devices on a patient’s health status, ie. blood pressure, weight, glucose levels, etc. It’s a product that is primarily for home bound patients that need remote monitoring vs. placement in a rehab center after hospital discharge. The information in our RPM solution can then be accessed by the physician/staff to determine the health status of the patient and whether or not a critical situation is at hand for the patient to go to the hospital, come in for a visit, or receive a nursing staff visit.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

HealthDatix - Chronic Care Management (CCM) Program

Centers for Medicaid and Medicare Services (CMS) introduced the Chronic Care Management (CCM) program in 2015 with the goal of filling patient care gaps and providing patient care at home.

HealthDatix Chronic Care Management (CCM) service was established to provide better care by engaging patients between visits by providing remote monitoring of patients. eat better, exercise more, take their medications, and live healthier lives. The CCM program delivers 20 minutes of non-face-to-face care coordination to Medicare eligible beneficiaries with two or more chronic conditions.

Target Markets: Physician Groups, ACO’s, Healthcare Systems

Assets. At June 30, 2019, we had $2,338,814 in total assets compared to $2,618,466 at December 31, 2018. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

Liabilities. At June 30, 2019, our total liabilities were $1,325,133 compared to $1,385,447 at December 31, 2018. Our current liabilities at June 30, 2019 consisted of accounts payable and accrued expenses of $657,563, accrued interest on notes payable of $18,630, amounts due to related parties of $128,476, deferred revenue of $2,617 notes payable of $445,593 and convertible notes payable of $72,254, whereas our current liabilities at December 31, 2018 consisted of accounts payable and accrued expenses of $480,270, accrued interest on notes payable of $32,265, amounts due to related parties of $145,367, deferred revenue of $9,192, notes payable of $52,500, convertible notes payable of $377,611, and derivative liability of $288,242.

Stockholders’ Equity. Our Stockholders’ Equity was $1,013,681 at June 30, 2019 compared to Stockholders Equity of $1,233,019 at December 31, 2018. This decrease was primarily due to an increase in accumulated deficit during the six months ended June 30, 2019.

threE Months Ended JUNE 30, 2019 as Compared to Three Months Ended JUNE 30, 2018

Revenues and Net Loss. We had $6,300 of revenue from our HealthDatix subsidiary and a net loss of $570,365 during the three months ended June 30, 2019, compared to $3,726 of revenue and a net loss of $726,247 during the three months ended June 30, 2018. The increase in revenue was due to revenue generated by our HealthDatix subsidiary.

General and Administrative Expenses. General and Administrative Expenses decreased to $198,953 from $310,873 for the three months ended June 30, 2019 from the three months ended June 30, 2018. For the three months ended June 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $14,254, depreciation expense of $247, legal and accounting fees of $15,787 employee benefits expenses (health and life insurance) of $2,925, travel and business meals expenses of $3,053, payroll expenses of $96,356, contract labor expenses of $4,500, bank service fees $45,443, rent expense of $7,533, franchise taxes of $3,781 and transfer agent fees of $5,074. For the three months ended June 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $24,175, depreciation expense of $432, legal and accounting fees of $26,500 employee benefits expenses (health and life insurance) of $11,623, marketing expense of $17,941, travel expenses of $3,859, payroll expenses of $103,344, contract labor expenses of $12,000, consulting fees expense of $89,400, exchange filing fees of $4,200, rent expense of $7,188, and transfer agent fees of $10,211. The decreases from the three months ended June 30, 2018 to the three months ended June 30, 2019 relate primarily due to: (i) a decrease in payroll expense and employee benefits, (ii) a decrease in bank service fees, and (iii) a decrease in consulting and fees expenses. Costs associated with the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported a gain on change in fair value of derivative liability of $152,107, loss on extinguishment of debt of $256,698 and interest expense of $91,066 for the three months ended June 30, 2019. We reported a loss on change in fair value of derivative liability of $86,090, loss on extinguishment of debt of $74,571 and interest expense of $76,577 for the three months ended June 30, 2018.

six Months Ended june 30, 2019 as Compared to six Months Ended june 30, 2019

Revenues and Net Loss. We had $11,625 of revenue from our HealthDatix subsidiary and a net loss of $1,129,762 during the six months ended June 30, 2019, compared to revenue of $7,918 and a net loss of $1,336,280 for the six months ended June 30, 2018. The increase in revenue was due to the revenue generated by our HealthDatix subsidiary.

General and Administrative Expenses. General and Administrative Expenses decreased to $389,217 for the six months ended June 30, 2019 from $545,137 for the six months ended June 30, 2018. For the six months ended June 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $31,904, depreciation expense of $495, legal and accounting fees of $40,242 employee benefits expenses (health and life insurance) of $6,199, travel and business meals expenses of $7,142, payroll expenses of $206,102, contract labor expenses of $14,500, bank service fees $46,048, rent expense of $15,262, franchise taxes of $3,781 and transfer agent fees of $17,542. For the six months ended June 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $46,699, depreciation expense of $863, legal and accounting fees of $44,610, employee benefits expenses (health and life insurance) of $21,891, marketing expense of $34,616, trade show expense of $5,543, travel and business meals expenses of $4,965, payroll expenses of $208,430, contact labor expenses of $24,200, commissions and fees expense of $21,000, consulting fees expense of $89,400, exchange filing fees of $10,810, rent expense of $14,235, and transfer agent fees of $17,875. The decreases from the six months ended June 30, 2018 to the six months ended June 30, 2019 relate primarily due to: (i) a decrease in payroll expense and employee benefits, (ii) a decrease in commissions and fees expenses, (iii) a decrease in consulting fees expenses and (iv) a decrease in exchange filing expense. Costs associated with the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported a gain on change in fair value of derivative liability of $98,944, loss on extinguishment of debt of $262,536 and interest expense of $224,319 for the six months ended June 30, 2019. We reported a loss on change in fair value of derivative liability of $204,191, loss on extinguishment of debt of $138,270 and interest expense of $92,841 for the six months ended June 30, 2018.

Liquidity and Capital Resources

General

As reflected in the accompanying consolidated financial statements, at June 30, 2019, we had $75,456 of cash and stockholders’ equity of $1,013,681. At December 31, 2018, we had $369 of cash and stockholders’ equity of $1,233,019.

Our primary capital requirements in 2019 are likely to arise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net cash used in operating activities was $216,922, for the six months ended June 30, 2019, compared to $492,032 for the six months ended June 30, 2018. Our primary use of operating cash flows from operating activities was from net losses of $1,129,762 and $1,336,280 for the six months ended June 30, 2019 and 2018, respectively. Additional contributing factors to the change were from depreciation expense of $494, amortization expense of $347,935, non-cash interest expense of $222,736, stock based compensation of $1,025, loss on the extinguishment of debt of $262,536, a change in fair value of derivative liability of ($98,944) decrease in accounts receivable of $4,505, a decrease in inventory of $85, a decrease in deposits of $1,720, an increase in accounts payable and accrued expenses of $177,293, and a decrease in deferred revenue of $6,575.

Net cash flows from investing activities was $0 for the six months ended June 30, 2019 and 2018, respectively.

Net Cash provided by financing activities was $292,009 for the six months ended June 30, 2019 compared to $533,500 for the six months ended June 30, 2018. The cash flows provided by financing activities for the six months ended June 30, 2019 was primarily from $168,500 in proceeds from issuance of convertible debentures, repayment of convertible debentures of $257,693, $393,093 in proceeds from notes payable, proceeds from related party loans d $11,254 and repayment of related party loans of $23,145. The cash flows provided by financing activities for the six months ended June 30, 2018 was primarily from $30,000 in proceeds from the sale of common stock and $503,500 in proceeds from issuance of convertible debentures.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not Required.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended June 30, 2019.

Item 1A. Risk Factors

Not required

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults upon Senior Securities.

None

Item 4. Removed and Reserved.

Item 5. Other Information.

None

Item 6. Exhibits

Exhibit No.		Description
31.1		Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Interim Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
32.2		Certification of the Interim Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Linkbase
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 20, 2019.


	iGambit Inc.
	/s/ John Salerno
	John Salerno
	Chief Executive Officer


	/s/ Elisa Luqman
	Elisa Luqman
	Chief Financial Officer and Principal Accounting Officer

Exhibit Index

Exhibit No.		Description
31.1		Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Interim Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
32.2		Certification of the Interim Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Linkbase
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

Chief Executive Officer Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John Salerno, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of iGambit Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 20, 2019

/s/ John Salerno

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

Chief Financial Officer Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Elisa Luqman, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of iGambit Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 20, 2019

/s/ Elisa Luqman

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

WRITTEN STATEMENT OF THE CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Executive Officer of iGambit Inc. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2019, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 20, 2019

/s/ John Salerno

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

WRITTEN STATEMENT OF THE CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Financial Officer of iGambit Inc. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2019, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 20, 2019

/s/ Elisa Luqman

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 igmb-20190630.xml XBRL INSTANCE FILE 0001479681 2019-01-01 2019-06-30 0001479681 2019-06-30 0001479681 2018-12-31 0001479681 igmb:OfficeEquipmentAndFixturesMember srt:MinimumMember 2019-01-01 2019-06-30 0001479681 igmb:OfficeEquipmentAndFixturesMember srt:MaximumMember 2019-01-01 2019-06-30 0001479681 igmb:ComputerHardwareMember 2019-01-01 2019-06-30 0001479681 igmb:ComputerSoftwareMember 2019-01-01 2019-06-30 0001479681 igmb:DevelopmentEquipmentMember 2019-01-01 2019-06-30 0001479681 igmb:SoftwareMember 2019-01-01 2019-06-30 0001479681 igmb:TechnologylicenseMember 2019-01-01 2019-06-30 0001479681 us-gaap:CustomerContractsMember 2019-01-01 2019-06-30 0001479681 igmb:FDA510KClearanceMember 2019-01-01 2019-06-30 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-06-30 0001479681 2018-01-01 2018-06-30 0001479681 igmb:SoftwareMember 2019-06-30 0001479681 us-gaap:CustomerContractsMember 2019-06-30 0001479681 igmb:FDA510KClearanceMember 2019-06-30 0001479681 igmb:TechnologylicenseMember 2019-06-30 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2019-06-30 0001479681 igmb:SoftwareMember 2018-12-31 0001479681 us-gaap:CustomerContractsMember 2018-12-31 0001479681 igmb:FDA510KClearanceMember 2018-12-31 0001479681 igmb:TechnologylicenseMember 2018-12-31 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001479681 us-gaap:StockOptionMember 2019-01-01 2019-06-30 0001479681 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001479681 us-gaap:StockOptionMember 2018-01-01 2018-06-30 0001479681 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001479681 us-gaap:StockOptionMember 2019-04-01 2019-06-30 0001479681 us-gaap:WarrantMember 2019-04-01 2019-06-30 0001479681 2019-04-01 2019-06-30 0001479681 us-gaap:StockOptionMember 2018-04-01 2018-06-30 0001479681 us-gaap:WarrantMember 2018-04-01 2018-06-30 0001479681 2018-04-01 2018-06-30 0001479681 igmb:Options1Member 2019-06-30 0001479681 igmb:Options2Member 2019-06-30 0001479681 igmb:Options3Member 2019-06-30 0001479681 igmb:Options4Member 2019-06-30 0001479681 igmb:Options5Member 2019-06-30 0001479681 2018-06-30 0001479681 2017-12-31 0001479681 igmb:Options1Member 2019-01-01 2019-06-30 0001479681 igmb:Options2Member 2019-01-01 2019-06-30 0001479681 igmb:Options3Member 2019-01-01 2019-06-30 0001479681 igmb:Options4Member 2019-01-01 2019-06-30 0001479681 igmb:Options5Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants1Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants2Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants3Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants4Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants5Member 2019-01-01 2019-06-30 0001479681 igmb:Warrants1Member 2019-06-30 0001479681 igmb:Warrants2Member 2019-06-30 0001479681 igmb:Warrants3Member 2019-06-30 0001479681 igmb:Warrants4Member 2019-06-30 0001479681 igmb:Warrants5Member 2019-06-30 0001479681 igmb:NoteholderMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:NoteholderMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteOneMember igmb:PrincipalMember 2017-03-01 2017-03-30 0001479681 igmb:ConvertibleNoteFiveMember igmb:PrincipalMember 2018-01-01 2018-01-10 0001479681 igmb:ConvertibleNoteFiveMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteFiveMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteSevenMember igmb:PrincipalMember 2018-03-01 2018-03-06 0001479681 igmb:ConvertibleNoteSevenMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteSevenMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteEightMember igmb:PrincipalMember 2018-05-01 2018-05-03 0001479681 igmb:ConvertibleNoteEightMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteEightMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteNineMember igmb:PrincipalMember 2018-06-01 2018-06-25 0001479681 igmb:ConvertibleNoteNineMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteNineMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteTenMember igmb:PrincipalMember 2018-08-01 2018-08-13 0001479681 igmb:ConvertibleNoteTenMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteTenMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteElevenMember igmb:PrincipalMember 2018-09-01 2018-09-17 0001479681 igmb:ConvertibleNoteTwelveMember 2019-01-01 2019-01-03 0001479681 igmb:ConvertibleNoteThirteenMember 2019-02-01 2019-02-15 0001479681 igmb:ConvertibleNoteFourteenMember 2019-03-01 2019-03-29 0001479681 igmb:ConvertibleNoteElevenMember igmb:PrincipalMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteElevenMember igmb:AccruedInterestMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteFifteenMember 2019-03-01 2019-03-29 0001479681 igmb:NoteholderMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteFiveMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteSevenMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteEightMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteNineMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteTenMember 2019-01-01 2019-06-30 0001479681 igmb:ConvertibleNoteElevenMember 2019-01-01 2019-06-30 0001479681 srt:MinimumMember 2019-01-01 2019-06-30 0001479681 srt:MaximumMember 2019-01-01 2019-06-30 0001479681 srt:MinimumMember 2018-01-01 2018-06-30 0001479681 srt:MaximumMember 2018-01-01 2018-06-30 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2019-01-01 2019-06-30 0001479681 us-gaap:SalesMember igmb:SecondCustomersMember 2019-01-01 2019-06-30 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2019-01-01 2019-06-30 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2018-01-01 2018-06-30 0001479681 us-gaap:SalesMember igmb:SecondCustomersMember 2018-01-01 2018-06-30 0001479681 us-gaap:SalesMember igmb:ThirdCustomerMember 2018-01-01 2018-06-30 0001479681 us-gaap:SalesMember igmb:FourthCustomerMember 2018-01-01 2018-06-30 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2018-01-01 2018-06-30 0001479681 2019-08-19 0001479681 us-gaap:CommonStockMember 2017-12-31 0001479681 us-gaap:CommonStockMember 2018-03-31 0001479681 us-gaap:CommonStockMember 2018-06-30 0001479681 us-gaap:CommonStockMember 2018-12-31 0001479681 us-gaap:CommonStockMember 2019-03-31 0001479681 us-gaap:CommonStockMember 2019-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001479681 us-gaap:RetainedEarningsMember 2017-12-31 0001479681 us-gaap:RetainedEarningsMember 2018-03-31 0001479681 us-gaap:RetainedEarningsMember 2018-06-30 0001479681 us-gaap:RetainedEarningsMember 2018-12-31 0001479681 us-gaap:RetainedEarningsMember 2019-03-31 0001479681 us-gaap:RetainedEarningsMember 2019-06-30 0001479681 us-gaap:TreasuryStockMember 2017-12-31 0001479681 us-gaap:TreasuryStockMember 2018-03-31 0001479681 us-gaap:TreasuryStockMember 2018-06-30 0001479681 us-gaap:TreasuryStockMember 2018-12-31 0001479681 us-gaap:TreasuryStockMember 2019-03-31 0001479681 us-gaap:TreasuryStockMember 2019-06-30 0001479681 2018-03-31 0001479681 2019-03-31 0001479681 2018-01-01 2018-12-31 0001479681 igmb:ConvertibleNoteFiveMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteTwelveMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteThirteenMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteFourteenMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteFifteenMember 2019-06-01 2019-06-24 0001479681 us-gaap:SubsequentEventMember igmb:ClinigenceHoldingsMember 2019-08-01 2019-08-09 0001479681 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001479681 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001479681 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001479681 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001479681 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001479681 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001479681 2018-01-01 2018-03-31 0001479681 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001479681 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001479681 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001479681 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001479681 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001479681 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001479681 2019-01-01 2019-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q 2019-06-30 false iGambit, Inc. 0001479681 --12-31 Non-accelerated Filer 2019 Q2

.001

100000000

800000000

10000000

Yes true true

P5Y

P7Y

P5Y

P3Y

P5Y

P10Y

P5Y

Indefinite

329

2617

9192

-1212323

10964

9341

8846

3801771

156925

644846

1396000

1000000

604000

156925

644846

1396000

1000000

604000

1577690

1229756

2224081

2572015

347935

21875000

10363000

20250000

1625000

8463000

1900000

20250000

1625000

21875000

8463000

1900000

10363000

20250000

20500000

200000

600000

700000

6500000

12250000

8463000

0.03

0.01

0.03

0.07

0.01

0.07

0.03

0.07

P7Y6M7D

P7Y4M28D

P7Y8M19D P6Y10M28D 2015-03-24 2017-04-06 2017-06-06 2017-06-06 2018-11-01

20250000

200000

600000

700000

6500000

12250000

2020-03-24 2027-04-06 2022-06-06 2027-06-06 2028-11-01

1625000

1875000

1900000

400000

0.03 0.12 0.21 0.62

0.03

0.12

0.1

P3Y2M27D

P3Y3M8D

P3Y1M24D P3Y9M

2017-01-01

2017-01-05

2018-02-05

2018-04-27

1625000

50000

25000

750000

1625000

50000

25000

750000

0.25

0.50

0.05

75000

478957

2746

101346

326189

19868

75000

240000

71732

5366

126000

60000

4342

83500

53957

4600

53000

38000

2120

53000

2120

33000

38000

33000

1320

38000

182683896

48693873

35446300

25674344

14859260

26247619

31762500

0.00

P9M11D

P1Y

P9M7D

P1Y

0.0244

0.0252

0.0207

0.0257

2.74

2.94

2.57

2.93

.22

.16

0.96

0.32

0.23

0.22

0.10

1.00

250000

128476

145367

15262

14235

P3Y

75000

388553890 2021-10-10 2021-11-07 2022-01-05 2023-02-05 2023-04-27

218454

61479

3699 3699

0.08

2017-03-31

2018-06-25

2018-07-10

2019-03-06

2019-05-03

2019-04-15

2019-05-30

2019-06-30

2019-10-30

2019-11-30

2020-02-15

2020-03-15

1013681

1233019

1618483

2368975

126196

132291

152254

214860

361587

398554

12891348

13248356

14061111

14480973

14884079

15207703

-9648569

-10258602

-11594882

-12462814

-13022211

-13592576

-1000000

2122045

1223455

false 000-55462

288242

66059

-482211 -928773 292913 1122211

250000

0.05

1500000

0.05 -250000 0.73

94268

38000

7417 1659 1259 810 810 5000 7600 7600 7600 7600

393093

0.06

If the closing of the Merger occurs (the “Closing”), the former Clinigence equityholders shall own 85% of iGambit’s issued and outstanding common stock and the former iGambit equityholders shall own 15% of iGambit’s issued and outstanding common stock, in each case on a fully-diluted, as converted basis as of immediately prior to the Closing (including options, warrants and other rights to acquire equity securities of iGambit).

398553890

214859994

388553890

204859994

112810

42313

26988

27073

10366

14871

75456

369

2338814

2618466

300

2020

2224081

2572015

1623

2118

1325133

1385447

288242

72254

377611

445593

52500

2617

9192

128476

145367

18630

32265

657563

480270

2338814

2618466

1000000

2013681 2233019

-13592576

-12462814

15207703

14480973

398554

214860

-4669

-7906

-1787

-4168

16294

15824

8087

7894

11625

7918

6300

3726

-741821

-900978

-374708

-489009

737152

893072

372921

484841

347935

173968

389217

545137

198953

310873

-1129762

-1336280

-570365

-726247

-387941

-435302

-195657

-237238

224319

92841

91066

76577

-262566

-138270

-256698

-74571

98944

152107

-86090

-28745

-0.00

-.01

-0.00

-.01

333669806

124456325

380608478

127632070

1025

88800

222736

91008

494

863

-216922

-492032

1720

33716

75456

369

50917

9449

75087

41468

292009

533500

23145

11254

30000

168500

503500

1583

1834

19868 15466 326189 257000

222500

224249

257693

30000

750

1500

14250

28500

15000

360591 713918 5345 15463 342758 698455 348103 146727 36967 402081 323624 548808

88800

3000

85800

1025

126196571

132290751

152253127

214859994

361587519

398553890

750000

1500000

5344180 15462376 146727525 36966371

3000000

Note 1 - Organization and Basis of Presentation   The consolidated financial statements presented are those of iGambit Inc., (the “Company”) and its wholly-owned subsidiary, HealthDatix, Inc. (“HealthDatix. The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States.   Interim Financial Statements   The following (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2019.

Note 2 – Summary of Significant Accounting Policies   Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  All intercompany accounts and transactions have been eliminated.   Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.   Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the six months ended June 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.   Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the six months ended June 30, 2019 and 2018.   iGambit is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.   Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the six months ended June 30, 2019 and 2018, respectively.   Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.   Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.   Inventory   Inventory consisting of finished products is stated at the lower of cost or net realizable value. Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Office equipment and fixtures</td> <td style="width: 4%"> </td> <td style="width: 17%">5 - 7 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Computer hardware</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Computer software</td> <td> </td> <td> 3 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Development equipment</td> <td> </td> <td>5 years</td></tr> </table>   Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Software</td> <td style="width: 4%"> </td> <td style="width: 17%">5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Technology license</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Purchased in process R&D</td> <td> </td> <td> Indefinite</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Customer contracts</td> <td> </td> <td>10 years</td></tr> </table>   Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.   Deferred Revenue   Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $2,617 and $9,192 as of June 30, 2019 and December 31, 2018, respectively.   Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.   Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.   Recent Accounting Pronouncements   We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 3 – Going Concern   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The Company has an accumulated deficit of $13,592,576, and a working capital deficit of $1,212,323 at June 30, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time.  The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments.  In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.   The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Property and Equipment   Property and equipment are carried at cost and consist of the following at June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Office equipment and fixtures</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,341</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,846</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Depreciation expense of $494 and $863 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Note 5 – Intangible Assets   Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Life</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-left: 5.4pt">Software</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">FDA 510K clearance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">In process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">Indefinite</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,577,690</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,229,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,224,081</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Amortization expense of $347,935 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Note 6 - Earnings (Loss) Per Common Share   The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the six months ended June 30, 2019 and 2018 as the result would be anti-dilutive.     <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td><td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">June 30,</td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Stock options</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">20,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">20,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,625,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,625,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">  Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">21,875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,363,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">21,875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,363,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Note 7 – Stock Based Compensation   Options   In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan").   Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of June 30, 2019, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.   The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock.  8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date.  There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.   Stock option activity during the six months ended June 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Options Outstanding</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant-Date Fair Value</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-left: 5.4pt">Options outstanding at December 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: right">$</td> <td style="width: 9%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">No option activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at  June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,463,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">6.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Options outstanding at  December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td> <td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.52</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at  June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">$</td> <td style="padding-bottom: 2.5pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">7.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Options outstanding at June 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">March 24, 2015</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">March 24, 2020</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">April 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">April 6, 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2022</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">November 1, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">0.01</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">November 1, 2028</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Warrants   In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expired on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.   Warrant activity during the six months ended June 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Warrants Outstanding</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 5.4pt">Warrants outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3.27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrant granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,900,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Warrants outstanding at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Warrants outstanding at June 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">January 1, 2017</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">October 10, 2021</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">January 1, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">November 7, 2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">January 5, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">January 5, 2022</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">February 5, 2018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">February 5, 2023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 27, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 27, 2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center">  Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Note 8 – Convertible Debt   Convertible Notes Payable   On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $240,000, convertible into shares of the Company’s common stock, and includes a back-ended note with principal of $120,000 that was funded on July 10, 2018. The back-ended Note, including accrued interest is due July 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted $71,732 of the principal balance and accrued interest of $5,366 to 48,693,873 shares of common stock. The principal balance of the note of $94,268, accrued interest of $7,417, and prepayment penalty of $5,000 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $60,000 and accrued interest of $4,342 to 35,446,300 shares of common stock.   On May 3, 2018, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35% applied to the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 130%. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $53,957 and accrued interest of $4,600 to 25,674,344 shares of common stock.   On June 25, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the remaining principal balance of $38,000 and accrued interest of $2,120 to 14,859,260 shares of common stock.   On August 13, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due May 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $2,120 to 26,247,619 shares of common stock.   On September 17, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $33,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due June 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the six months ended June 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $1,320 to 31,762,500 shares of common stock.   On January 3, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,659, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On February 15, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due November 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,259, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On March 29, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due February 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $810, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below). On May 22, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $280, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 9) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated January 10, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated March 6, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated May 3, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated June 25, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated August 13, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated September 17, 2018 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $218,454 and $61,479 was recorded for the six months ended June 30, 2019 and 2018, respectively.   The Company issued convertible debentures in the amount of $75,000 to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the year. Interest expense on the convertible debentures of $3,699 was recorded for the six months ended June 30, 2019 and 2018, respectively.   Convertible notes payable at June 30, 2019 and December 31, 2018 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Total face value of notes</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">478,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,746</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,346</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">377,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Note 9 – Derivative Liability   The Company has determined that the conversion feature embedded in the convertible notes described in Note 8 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception. The Company used the Binomial Option Pricing model to value the conversion features.   The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">     June 30,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">December 31,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Annual dividend yield</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.78 - 1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.77 - 1.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.44% - 2.52%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.07% - 2.57%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 274% - 294%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 257% - 293%</td><td style="text-align: left"> </td></tr> </table>   Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Note 10 – Notes Payable   On June 24, 2019, the Company entered into a secured promissory note with Clinigence Holdings, Inc. (“Clinigence”) for proceeds of $393,093, of which $293,093 was utilized to pay outstanding principal, accrued interest and penalties of certain convertible notes payable, and $100,000 was utilized for working capital. The note bears interest at a rate of 6% and is due upon the earlier of December 24, 2019 or the Merger Agreement (See note 16).   Notes payable at June 30, 2019 and December 31, 2018 consists of loans to HealthDatix from 3 individuals totaling $52,500. The loans do not bear interest and there are no specific terms for repayment.

Note 11 – Stock Transactions   Designation of Preferred Stock   On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company.   Common Stock Issued   On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share.   In connection with the convertible notes payable (see Note 8 above) the noteholders converted $326,189 of principal balance and $19,868 of accrued interest to 182,683,896 shares of common stock during the six months ended June 30, 2019. The stock issued was determined based on the terms of the convertible notes.

Note 12 - Income Taxes   A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 – Concentrations and Credit Risk   Sales and Accounts Receivable   HealthDatix had sales to two customers which accounted for approximately 22% and 16%, respectively of HealthDatix’s total sales for the six months ended June 30, 2019. One customer accounted for approximately 96% of accounts receivable at June 30, 2019.   HealthDatix had sales to four customers which accounted for approximately 32%, 23%, 22%, and 10%, respectively of HealthDatix’s total sales for the six months ended June 30, 2018. One customer accounted for 100% of accounts receivable at June 30, 2018.   Cash   Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at June 30, 2019 and December 31, 2018, respectively.

Note 14 - Related Party Transactions   Amounts Due to Related Parties   Amounts due to related parties with balances of $128,476 and $145,367 at June 30, 2019 and December 31, 2018, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 – Commitments and Contingencies   Lease Commitment   The Company was obligated under an operating lease for its premises in Smithtown, New York that expired on May 31, 2019. The lease was not renewed and the officers of the Company are providing office space to the Company at no charge.   Rent expense of $15,262 and $14,235 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.   Employment Arrangements With Executive Officers   Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 – Subsequent Events   On August 9, 2019, the Company entered into a definitive merger agreement with Clinigence Holdings, Inc. pursuant to which the companies will combine in a stock-for-stock merger transaction. Pursuant to the merger agreement, iGambit shall issue newly-issued shares of common stock, on a fully-diluted pro rata basis, to the equity holders of Clinigence by means of a reverse triangular merger in which a wholly owned subsidiary of iGambit shall merge with and into Clinigence, with Clinigence continuing as the surviving corporation (the “Merger”). If the closing of the Merger occurs (the “Closing”), the former Clinigence equityholders shall own 85% of iGambit’s issued and outstanding common stock and the former iGambit equityholders shall own 15% of iGambit’s issued and outstanding common stock, in each case on a fully-diluted, as converted basis as of immediately prior to the Closing (including options, warrants and other rights to acquire equity securities of iGambit).

Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the six months ended June 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the six months ended June 30, 2019 and 2018.   iGambit is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventory   Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Office equipment and fixtures</td> <td style="width: 4%"> </td> <td style="width: 17%">5 - 7 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Computer hardware</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Computer software</td> <td> </td> <td> 3 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Development equipment</td> <td> </td> <td>5 years</td></tr> </table>

Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Software</td> <td style="width: 4%"> </td> <td style="width: 17%">5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Technology license</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Purchased in process R&D</td> <td> </td> <td> Indefinite</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Customer contracts</td> <td> </td> <td>10 years</td></tr></table>

Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue   Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $2,617 and $9,192 as of June 30, 2019 and December 31, 2018, respectively.

Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Recent Accounting Pronouncements   We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the six months ended June 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Office equipment and fixtures</td> <td style="width: 4%"> </td> <td style="width: 17%">5 - 7 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Computer hardware</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Computer software</td> <td> </td> <td> 3 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Development equipment</td> <td> </td> <td>5 years</td></tr></table> Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; width: 50%"> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td style="width: 79%">Software</td> <td style="width: 4%"> </td> <td style="width: 17%">5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Technology license</td> <td> </td> <td>5 years</td></tr> <tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)"> <td>Purchased in process R&D</td> <td> </td> <td> Indefinite</td></tr> <tr style="vertical-align: top; text-align: left; background-color: White"> <td>Customer contracts</td> <td> </td> <td>10 years</td></tr></table>

Property and equipment are carried at cost and consist of the following at June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Office equipment and fixtures</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,341</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,846</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Life</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-left: 5.4pt">Software</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">FDA 510K clearance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">In process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">Indefinite</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,577,690</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,229,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,224,081</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the six months ended June 30, 2019 and 2018 as the result would be anti-dilutive.     <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td><td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">June 30,</td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Stock options</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">20,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">20,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,625,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,625,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">  Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">21,875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,363,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">21,875,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,363,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Stock option activity during the six months ended June 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Options Outstanding</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant-Date Fair Value</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-left: 5.4pt">Options outstanding at December 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: right">$</td> <td style="width: 9%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">No option activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at  June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,463,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">6.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Options outstanding at  December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td> <td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.52</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at  June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">$</td> <td style="padding-bottom: 2.5pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">7.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Options outstanding at June 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">March 24, 2015</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">March 24, 2020</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">April 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">April 6, 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2022</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">June 6, 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">November 1, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">0.01</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">November 1, 2028</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Warrant activity during the six months ended June 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Warrants Outstanding</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 5.4pt">Warrants outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3.27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrant granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,900,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Warrants outstanding at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Warrants outstanding at June 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">January 1, 2017</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">October 10, 2021</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">January 1, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">November 7, 2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">January 5, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">January 5, 2022</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">February 5, 2018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">February 5, 2023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 27, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 27, 2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center">  Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Convertible notes payable at June 30, 2019 and December 31, 2018 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Total face value of notes</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">478,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,746</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,346</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">377,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">     June 30,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">December 31,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt; text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Annual dividend yield</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.78 - 1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.77 - 1.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.44% - 2.52%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.07% - 2.57%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 274% - 294%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 257% - 293%</td><td style="text-align: left"> </td></tr></table>

-177293

58213

-6575

-7450

4505

5128

-570365

-1336280

-610033

-1336280

-610033

-559397

-570365

-559397

false

EX-101.SCH 7 igmb-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Convertible Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 9 - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 10 - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 11 - Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 12 - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 13 - Concentrations and Credit Risk link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 14 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 15 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 16 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 4 - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 5 - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 7 - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 8 - Convertible Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 9 - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 15 - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note 3 - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Note 4 - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note 4 - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Note 5 - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Note 5 - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Note 7 - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Note 7 - Stock Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Note 7 - Stock Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Note 7 - Stock Based Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Note 8 - Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Note 8 - Convertible Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Note 9 - Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Note 10 - Note Payable (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Note 11 - Stock Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Note 15 - Commitments and Contingencies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Note 16- Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 igmb-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 igmb-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 igmb-20190630_lab.xml XBRL LABEL FILE Property, Plant and Equipment, Type [Axis] Office equipment and fixtures Range [Axis] Minimum Maximum Computer hardware Computer software Development equipment Finite-Lived Intangible Assets by Major Class [Axis] Software Technology license Customer contracts FDA 510K clearance In process research and development Antidilutive Securities [Axis] Options Warrant Award Type [Axis] Options One Options Two Options Three Options Four Options Five Warrants One Warrants Two Warrants Three Warrants Four Warrants Five Short-term Debt, Type [Axis] Noteholder Debt Security Category [Axis] Principal Accrued interest 8% Convertible Note ConvertibleNoteFiveMember ConvertibleNoteSevenMember ConvertibleNoteEightMember ConvertibleNoteNineMember ConvertibleNoteTenMember ConvertibleNoteElevenMember ConvertibleNoteTwelveMember ConvertibleNoteThirteenMember ConvertibleNoteFourteenMember ConvertibleNoteFifteenMember Concentration Risk Benchmark [Axis] Sales [Member] Customer [Axis] First Customers [Member] Second Customers [Member] Accounts Receivable [Member] One Customer [Member] Third Customer [Member] Fourth Customer [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Treasury Stock Subsequent Event Type [Axis] Subsequent Event [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Clinigence Holdings Document and Entity Information: Entity Registrant Name Document Type Document Period End Date Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Filer Category Entity's Reporting Status Current Entity Emerging Growth Company Entity Small Business Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Shell Company File Number Document Fiscal Year Focus Document Fiscal Period Focus Entity extended transition period? Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Inventory Total current assets Other assets Property and equipment, net Intangilbe assets, net Deposits Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses Accrued interest on notes payable Amounts due to related parties Deferred revenue Notes payable Convertible notes payable, net Derivative liability Total current liabilities Stockholders' equity Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2019 and 2018, respectively Common stock, $.001 par value; authorized - 800,000,000 shares; 398,553,890 and 214,859,994 shares issued and 388,553,890 and 204,859,994 shares outstanding (net of treasury shares) as of June 30, 2019 and December 31, 2018, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity before Treasury stock Less: Treasury stock; 10,000,000 shares, at cost Total stockholders' equity Liabilities and equity Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock Income Statement [Abstract] Sales Cost of Sales Gross profit (loss) Operating Expenses General and Administrative Expense Amortization Total operating expenses Loss from operations Other income (expenses) Change in fair value of derivative liability Loss on extinguishment of debt Interest Expense Total other income (expenses) Net loss Basic and fully diluted loss per common share: Net loss per common share Weighted average common shares outstanding - basic and fully diluted Statement [Table] Statement [Line Items] Stockholders' Equity, beginning of period, Value Stockholders' Equity, beginning of period, Shares Common stock issued for cash, Value Common stock issued for cash, Shares Compensation for vested stock options Notes payable and accrued interest converted to common stock, Value Notes payable and accrued interest converted to common stock, Shares Common stock issued for services, Value Common stock issued for services, Shares Net loss Stockholders' Equity, end of period, Value Stockholders' Equity, end of period, Shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation Non cash interest expense Stock-based compensation expense Loss on extinguishment of debt Change in fair value of derivative liability Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Deposits Accounts payable and accrued expenses Deferred revenue NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible debentures Repayments of convertible debentures Proceeds from sale of common stock Proceeds from notes payable Proceeds from related party loans Repayments of related party loans NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the period for Interest Non-cash investing and financing activities: Debt discount related to derivative liability Notes payable converted to common stock Common stock issued in payment of accrued interest Disclosure Text Block [Abstract] Note 1 - Organization and Basis of Presentation Note 2 - Summary of Significant Accounting Policies Note 3 - Going Concern Note 4 - Property and Equipment Note 5 - Intangible Assets EX-101.PRE 11 igmb-20190630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 19, 2019
Document and Entity Information:
Entity Registrant Name	iGambit, Inc.
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Entity Central Index Key	0001479681
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		388,553,890
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
File Number	000-55462
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity extended transition period?	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 75,456	$ 369
Accounts receivable	10,366	14,871
Inventory	26,988	27,073
Total current assets	112,810	42,313
Other assets
Property and equipment, net	1,623	2,118
Intangilbe assets, net	2,224,081	2,572,015
Deposits	300	2,020
Total Assets	2,338,814	2,618,466
Current liabilities
Accounts payable and accrued expenses	657,563	480,270
Accrued interest on notes payable	18,630	32,265
Amounts due to related parties	128,476	145,367
Deferred revenue	2,617	9,192
Notes payable	445,593	52,500
Convertible notes payable, net	72,254	377,611
Derivative liability	0	288,242
Total current liabilities	1,325,133	1,385,447
Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2019 and 2018, respectively	0	0
Common stock, $.001 par value; authorized - 800,000,000 shares; 398,553,890 and 214,859,994 shares issued and 388,553,890 and 204,859,994 shares outstanding (net of treasury shares) as of June 30, 2019 and December 31, 2018, respectively	398,554	214,860
Additional paid-in capital	15,207,703	14,480,973
Accumulated deficit	(13,592,576)	(12,462,814)
Total stockholders' equity before Treasury stock	2,013,681	2,233,019
Less: Treasury stock; 10,000,000 shares, at cost	(1,000,000)	(1,000,000)
Total stockholders' equity	1,013,681	1,233,019
Liabilities and equity	$ 2,338,814	$ 2,618,466

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	398,553,890	214,859,994
Common stock, shares outstanding	388,553,890	204,859,994
Treasury stock	10,000,000	10,000,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Sales	$ 6,300	$ 3,726	$ 11,625	$ 7,918
Cost of Sales	8,087	7,894	16,294	15,824
Gross profit (loss)	(1,787)	(4,168)	(4,669)	(7,906)
Operating Expenses
General and Administrative Expense	198,953	310,873	389,217	545,137
Amortization	173,968	173,968	347,935	347,935
Total operating expenses	372,921	484,841	737,152	893,072
Loss from operations	(374,708)	(489,009)	(741,821)	(900,978)
Other income (expenses)
Change in fair value of derivative liability	152,107	(86,090)	98,944
Loss on extinguishment of debt	(256,698)	(74,571)	(262,566)	(138,270)
Interest Expense	(91,066)	(76,577)	(224,319)	(92,841)
Total other income (expenses)	(195,657)	(237,238)	(387,941)	(435,302)
Net loss	$ (570,365)	$ (726,247)	$ (1,129,762)	$ (1,336,280)
Basic and fully diluted loss per common share:
Net loss per common share	$ (0.00)	$ (.01)	$ (0.00)	$ (.01)
Weighted average common shares outstanding - basic and fully diluted	380,608,478	127,632,070	333,669,806	124,456,325

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Treasury Stock	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2017	$ 126,196	$ 12,891,348	$ (9,648,569)	$ (1,000,000)	$ 2,368,975
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2017	126,196,571
Common stock issued for cash, Value	$ 750	14,250			15,000
Common stock issued for cash, Shares	750,000
Notes payable and accrued interest converted to common stock, Value	$ 5,345	342,758			348,103
Notes payable and accrued interest converted to common stock, Shares	5,344,180
Net loss			(610,033)		(610,033)
Stockholders' Equity, end of period, Value at Mar. 31, 2018	$ 132,291	13,248,356	(10,258,602)	(1,000,000)	2,122,045
Stockholders' Equity, end of period, Shares at Mar. 31, 2018	132,290,751
Common stock issued for cash, Value	$ 1,500	28,500			30,000
Common stock issued for cash, Shares	1,500,000
Notes payable and accrued interest converted to common stock, Value	$ 15,463	698,455			713,918
Notes payable and accrued interest converted to common stock, Shares	15,462,376
Common stock issued for services, Value	$ 3,000	85,800			88,800
Common stock issued for services, Shares	3,000,000
Net loss			(1,336,280)		(1,336,280)
Stockholders' Equity, end of period, Value at Jun. 30, 2018	$ 152,254	14,061,111	(11,594,882)	(1,000,000)	1,618,483
Stockholders' Equity, end of period, Shares at Jun. 30, 2018	152,253,127
Stockholders' Equity, beginning of period, Value at Dec. 31, 2018	$ 214,860	14,480,973	(12,462,814)	(1,000,000)	1,233,019
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2018	214,859,994
Compensation for vested stock options		1,025			1,025
Notes payable and accrued interest converted to common stock, Value	$ 146,727	402,081			548,808
Notes payable and accrued interest converted to common stock, Shares	146,727,525
Net loss			(559,397)		(559,397)
Stockholders' Equity, end of period, Value at Mar. 31, 2019	$ 361,587	14,884,079	(13,022,211)	(1,000,000)	1,223,455
Stockholders' Equity, end of period, Shares at Mar. 31, 2019	361,587,519
Notes payable and accrued interest converted to common stock, Value	$ 36,967	323,624			360,591
Notes payable and accrued interest converted to common stock, Shares	36,966,371
Net loss			(570,365)		(570,365)
Stockholders' Equity, end of period, Value at Jun. 30, 2019	$ 398,554	$ 15,207,703	$ (13,592,576)	$ (1,000,000)	$ 1,013,681
Stockholders' Equity, end of period, Shares at Jun. 30, 2019	398,553,890

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (570,365)	$ (726,247)	$ (1,129,762)	$ (1,336,280)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation			494	863
Amortization	173,968	173,968	347,935	347,935
Non cash interest expense			222,736	91,008
Stock-based compensation expense			1,025	88,800
Loss on extinguishment of debt	256,698	74,571	262,566	138,270
Change in fair value of derivative liability	(152,107)	86,090	(98,944)		$ 28,745
Changes in operating assets and liabilities:
Accounts receivable			4,505	5,128
Inventory			85	0
Prepaid expenses and other current assets			0	33,716
Deposits			1,720	0
Accounts payable and accrued expenses			177,293	(58,213)
Deferred revenue			(6,575)	(7,450)
NET CASH USED IN OPERATING ACTIVITIES			(216,922)	(492,032)
CASH FLOWS FROM INVESTING ACTIVITIES			0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures			168,500	503,500
Repayments of convertible debentures			(257,693)	0
Proceeds from sale of common stock			0	30,000
Proceeds from notes payable			393,093	0
Proceeds from related party loans			11,254	0
Repayments of related party loans			(23,145)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES			292,009	533,500
NET INCREASE IN CASH			75,087	41,468
CASH - BEGINNING OF PERIOD			369	9,449	9,449
CASH - END OF PERIOD	$ 75,456	$ 50,917	75,456	50,917	$ 369
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for Interest			1,583	1,834
Non-cash investing and financing activities:
Debt discount related to derivative liability			222,500	224,249
Notes payable converted to common stock			326,189	257,000
Common stock issued in payment of accrued interest			$ 19,868	$ 15,466

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Basis of Presentation

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 1 - Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Interim Financial Statements

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 2 - Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Revenue Recognition

iGambit is a holding company and has no sources of revenue.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

Inventory

Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation

Office equipment and fixtures		5 - 7 years
Computer hardware		5 years
Computer software		3 years
Development equipment		5 years

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software		5 years
Technology license		5 years
Purchased in process R&D		Indefinite
Customer contracts		10 years

Long-Lived Assets

Deferred Revenue

Stock-Based Compensation

Income Taxes

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 3 - Going Concern

Note 3 – Going Concern

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 4 - Property and Equipment

Note 4 – Property and Equipment

Property and equipment are carried at cost and consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018

Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,341		8,846
	$	1,623	$	2,118

Depreciation expense of $494 and $863 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 5 - Intangible Assets

Note 5 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018		Life

Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		1,577,690		1,229,756
	$	2,224,081	$	2,572,015

Amortization expense of $347,935 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 6 - Earnings (Loss) Per Common Share

Note 6 - Earnings (Loss) Per Common Share

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Stock options		20,250,000		8,463,000		20,250,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Total shares excluded from calculation		21,875,000		10,363,000		21,875,000		10,363,000

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 7 - Stock Based Compensation

Note 7 – Stock Based Compensation

Options

Stock option activity during the six months ended June 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at June 30, 2018		8,463,000		$	0.07		0.07		6.91
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options expired		(250,000	)		0.05		—
Options outstanding at June 30, 2019		20,250,000		$	0.03	$	0.03		7.72

Options outstanding at June 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
	April 6, 2017		600,000		600,000	$	0.03		April 6, 2027
	June 6, 2017		700,000		700,000	$	0.07		June 6, 2022
	June 6, 2017		6,500,000		6,500,000	$	0.07		June 6, 2027
	November 1, 2018		12,250,000		12,250,000	$	0.01		November 1, 2028
	Total		20,250,000		20,250,000

Warrants

Warrant activity during the six months ended June 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at June 30, 2018		1,900,000		$	0.21	$	0.12		3.75
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at June 30, 2019		1,625,000		$	0.03	$	0.03		3.15

Warrants outstanding at June 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
	January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
	January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
	February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
	April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
	Total		1,625,000		1,625,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 8 - Convertible Debt

Note 8 – Convertible Debt

Convertible Notes Payable

Convertible notes payable at June 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018

Total face value of notes	$	75,000	$	478,957
Less: Discount		2,746		101,346
Balance	$	72,254	$	377,611

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Derivative Liability

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Note 9 - Derivative Liability

Note 9 – Derivative Liability

	June 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 10 - Note Payable

Note 10 – Notes Payable

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 11 - Stock Transactions

Note 11 – Stock Transactions

Designation of Preferred Stock

Common Stock Issued

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Income Taxes

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 12 - Income Taxes

Note 12 - Income Taxes

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 13 - Concentrations and Credit Risk

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

Cash

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 14 - Related Party Transactions

Note 14 - Related Party Transactions

Amounts Due to Related Parties

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 15 - Commitments and Contingencies

Note 15 – Commitments and Contingencies

Lease Commitment

Rent expense of $15,262 and $14,235 was charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Employment Arrangements With Executive Officers

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 16 - Subsequent Events

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Note 16 - Subsequent Events

Note 16 – Subsequent Events

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Policy Text Block [Abstract]

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

Use of Estimates in the Preparation of Financial Statements

Fair Value Measurements

Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Convertible Instruments

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Revenue Recognition

Revenue Recognition

iGambit is a holding company and has no sources of revenue.

Advertising Costs

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the six months ended June 30, 2019 and 2018, respectively.

Cash and Cash Equivalents

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation

Office equipment and fixtures		5 - 7 years
Computer hardware		5 years
Computer software		3 years
Development equipment		5 years

Amortization

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software		5 years
Technology license		5 years
Purchased in process R&D		Indefinite
Customer contracts		10 years

Long-Lived Assets

Long-Lived Assets

Deferred Revenue

Deferred Revenue

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Fair value assets and liabilities measured on recurring basis

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the six months ended June 30, 2019 and year ended December 31, 2018.

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Schedule of estimated lives of respective assets

Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures		5 - 7 years
Computer hardware		5 years
Computer software		3 years
Development equipment		5 years

Schedule of estimated lives of the respective assets of intangible assets

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software		5 years
Technology license		5 years
Purchased in process R&D		Indefinite
Customer contracts		10 years

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Schedule of property, plant and equipment

Property and equipment are carried at cost and consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018

Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,341		8,846
	$	1,623	$	2,118

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Schedule of intangible assets

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at June 30, 2019 and December 31, 2018:

	2019		2018		Life

Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		1,577,690		1,229,756
	$	2,224,081	$	2,572,015

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Computation of diluted net income (loss) per share

The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the six months ended June 30, 2019 and 2018 as the result would be anti-dilutive.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Stock options		20,250,000		8,463,000		20,250,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Total shares excluded from calculation		21,875,000		10,363,000		21,875,000		10,363,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Schedule of stock option activities

Stock option activity during the six months ended June 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at June 30, 2018		8,463,000		$	0.07		0.07		6.91
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options expired		(250,000	)		0.05		—
Options outstanding at June 30, 2019		20,250,000		$	0.03	$	0.03		7.72

Schedule of stock options outstanding

Options outstanding at June 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
	April 6, 2017		600,000		600,000	$	0.03		April 6, 2027
	June 6, 2017		700,000		700,000	$	0.07		June 6, 2022
	June 6, 2017		6,500,000		6,500,000	$	0.07		June 6, 2027
	November 1, 2018		12,250,000		12,250,000	$	0.01		November 1, 2028
	Total		20,250,000		20,250,000

Schedule of Warrants, Activity

Warrant activity during the six months ended June 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at June 30, 2018		1,900,000		$	0.21	$	0.12		3.75
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at June 30, 2019		1,625,000		$	0.03	$	0.03		3.15

Schedule of Outstanding Warrants

Warrants outstanding at June 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
	January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
	January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
	February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
	April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
	Total		1,625,000		1,625,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Text Block [Abstract]

Schedule of convertible notes payable

Convertible notes payable at June 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018

Total face value of notes	$	75,000	$	478,957
Less: Discount		2,746		101,346
Balance	$	72,254	$	377,611

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Derivative Liability (Tables)

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Schedule of Valuation Assumptions

	June 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018
Liabilities:
Balance of derivative liabilities - beginning of year			$ 288,242	$ 66,059
Issued			292,913	1,122,211
Converted			(482,211)	(928,773)
Change in fair value of derivative liabilities	$ (152,107)	$ 86,090	(98,944)	28,745
Balance of derivative liabilities - end of period	$ 0		$ 0	$ 288,242

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2019
Computer hardware
Office equipment useful life	5 years
Computer software
Office equipment useful life	3 years
Development equipment
Office equipment useful life	5 years
Maximum \| Office equipment and fixtures
Office equipment useful life	7 years
Minimum \| Office equipment and fixtures
Office equipment useful life	5 years

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Jun. 30, 2019
Technology license
Intangible assets useful life	5 years
Customer contracts
Intangible assets useful life	10 years
FDA 510K clearance
Intangible assets useful life	5 years
In process research and development
Intangible assets useful life	Indefinite
Software
Intangible assets useful life	5 years

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Narratives) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Disclosure Text Block [Abstract]
Advertising costs	$ 329	$ 0
Deferred revenue	$ 2,617		$ 9,192

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Accumulated deficit	$ (13,592,576)	$ (12,462,814)
Working capital deficit	$ (1,212,323)

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Office equipment and fixtures	$ 10,964	$ 10,964
Less: accumulated depreciation	9,341	8,846
Property, Plant and Equipment, Net	$ 1,623	$ 2,118

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disclosure Text Block [Abstract]
Depreciation expense	$ 494	$ 863

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Details) - USD ($)	6 Months Ended
Note 5 - Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Intangible Assets, Gross	$ 3,801,771	$ 3,801,771
Less: Accumulated amortization	1,577,690	1,229,756
Intangible Assets, Net	2,224,081	2,572,015
Technology license
Intangible Assets, Gross	$ 1,000,000	1,000,000
Intangible assets useful life	5 years
Customer contracts
Intangible Assets, Gross	$ 644,846	644,846
Intangible assets useful life	10 years
FDA 510K clearance
Intangible Assets, Gross	$ 1,396,000	1,396,000
Intangible assets useful life	5 years
In process research and development
Intangible Assets, Gross	$ 604,000	604,000
Intangible assets useful life	Indefinite
Software
Intangible Assets, Gross	$ 156,925	$ 156,925
Intangible assets useful life	5 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disclosure Text Block [Abstract]
Amortization expense	$ 347,935	$ 347,935

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total shares excluded from calculation	21,875,000	10,363,000	21,875,000	10,363,000
Warrant
Total shares excluded from calculation	1,625,000	1,900,000	1,625,000	1,900,000
Options
Total shares excluded from calculation	20,250,000	8,463,000	20,250,000	8,463,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details) - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disclosure Text Block [Abstract]
Options, Outstanding, Beginning Balance	20,500,000	8,463,000
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.03	$ 0.07
Options, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.07
Options, Outstanding, Beginning Weighted Average Remaining Contractual Term	7 years 6 months 7 days	7 years 4 months 28 days
Options, Expired	(250,000)
Options, Expired , Weighted Average Exercise Price	$ 0.05
Options, Outstanding, Ending Balance	20,250,000	8,463,000
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.03	$ 0.07
Options, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.07
Options, Outstanding, Ending Weighted Average Remaining Contractual Term	7 years 8 months 19 days	6 years 10 months 28 days

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details 1) - $ / shares	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Number of Outstanding	20,250,000	20,500,000	8,463,000	8,463,000
Number Exercisable	20,250,000
Exercise price	$ 0.03	$ 0.03	$ 0.07	$ 0.07
Options Two
Issued Date	Apr. 06, 2017
Number of Outstanding	600,000
Number Exercisable	600,000
Exercise price	$ 0.03
Options outstanding Expiration Date	Apr. 06, 2027
Options Three
Issued Date	Jun. 06, 2017
Number of Outstanding	700,000
Number Exercisable	700,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 06, 2022
Options Four
Issued Date	Jun. 06, 2017
Number of Outstanding	6,500,000
Number Exercisable	6,500,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 06, 2027
Options Five
Issued Date	Nov. 01, 2018
Number of Outstanding	12,250,000
Number Exercisable	12,250,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Nov. 01, 2028
Options One
Issued Date	Mar. 24, 2015
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Mar. 24, 2020

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details 2) - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Text Block [Abstract]
Warrants, Outstanding, Beginning Balance	1,875,000	400,000
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.12	$ 0.62
Warrants, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.12	$ 0.1
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 2 months 27 days	3 years 3 months 8 days
Warrants, Granted		1,500,000
Warrants, Granted, Weighted Average Exercise Price		$ 0.05
Warrants expired	(250,000)
Warrants expired, Weighted Average Exercise Price	$ 0.73
Warrants, Outstanding, Ending Balance	1,625,000	1,900,000
Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.03	$ 0.21
Warrants, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.12
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 1 month 24 days	3 years 9 months

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details 3)	6 Months Ended
Note 7 - Stock Based Compensation (Details 3)	Jun. 30, 2019 $ / shares shares
Number of Outstanding	1,625,000
Number Exercisable	1,625,000
Warrants Two
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	Nov. 07, 2021
Warrants Three
Issued Date	Jan. 05, 2017
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	Jan. 05, 2022
Warrants Four
Issued Date	Feb. 05, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price \| $ / shares	$ 0.05
Expiration Date	Feb. 05, 2023
Warrants Five
Issued Date	Apr. 27, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price \| $ / shares	$ 0.05
Expiration Date	Apr. 27, 2023
Warrants One
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.25
Expiration Date	Oct. 10, 2021

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Total face value of notes	$ 75,000	$ 478,957
Less: Discount	2,746	101,346
Balance	$ 72,254	$ 377,611

XML 57 R46.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Details Narrative) - USD ($)						1 Months Ended						6 Months Ended
Note 8 - Convertible Debt (Details Narrative) - USD ($)	Jan. 03, 2019	Aug. 13, 2018	May 03, 2018	Mar. 06, 2018	Jan. 10, 2018	Jun. 24, 2019	Mar. 29, 2019	Feb. 15, 2019	Sep. 17, 2018	Jun. 25, 2018	Mar. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Interest expense on the convertible notes												$ 218,454	$ 61,479
Interest expense on the convertible debentures												$ 3,699	$ 3,699
Maturity date												Mar. 31, 2017
ConvertibleNoteTwelveMember
Debt Conversion, Converted Instrument, Amount	$ 38,000
Interest rate	8.00%
Maturity date	Oct. 30, 2019
Principal payment						$ 38,000
Payment of accrued interest						1,659
Prepayment penalty						7,600
ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Shares Issued												25,674,344
ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Shares Issued												35,446,300
ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Shares Issued												48,693,873
Principal payment						94,268
Payment of accrued interest						7,417
Prepayment penalty						5,000
ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Shares Issued												26,247,619
ConvertibleNoteThirteenMember
Debt Conversion, Converted Instrument, Amount								$ 38,000
Interest rate								8.00%
Maturity date								Nov. 30, 2019
Principal payment						38,000
Payment of accrued interest						1,259
Prepayment penalty						7,600
ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Shares Issued												31,762,500
ConvertibleNoteFourteenMember
Debt Conversion, Converted Instrument, Amount							$ 38,000
Interest rate							8.00%
Maturity date							Feb. 15, 2020
Principal payment						38,000
Payment of accrued interest						810
Prepayment penalty						7,600
ConvertibleNoteFifteenMember
Debt Conversion, Converted Instrument, Amount							$ 38,000
Interest rate							8.00%
Maturity date							Mar. 15, 2020
Principal payment						38,000
Payment of accrued interest						810
Prepayment penalty						$ 7,600
ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Shares Issued												14,859,260
Noteholder
Debt Conversion, Converted Instrument, Shares Issued												182,683,896
Principal \| ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Amount			$ 83,500									$ 53,957
Interest rate			8.00%
Maturity date			May 03, 2019
Principal \| ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Amount				$ 126,000								60,000
Interest rate				8.00%
Maturity date				Mar. 06, 2019
Principal \| ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Amount					$ 240,000							71,732
Interest rate					8.00%
Maturity date					Jul. 10, 2018
Principal \| ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Amount		$ 53,000										53,000
Interest rate		8.00%
Maturity date		May 30, 2019
Principal \| ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Amount									$ 33,000			33,000
Interest rate									8.00%
Maturity date									Jun. 30, 2019
Principal \| ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Amount										$ 53,000		38,000
Interest rate										8.00%
Maturity date										Apr. 15, 2019
Principal \| 8% Convertible Note
Debt Conversion, Converted Instrument, Amount											$ 75,000
Interest rate											8.00%
Maturity date											Jun. 25, 2018
Principal \| Noteholder
Debt Conversion, Converted Instrument, Amount												326,189
Accrued interest \| ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Amount												4,600
Accrued interest \| ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Amount												4,342
Accrued interest \| ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Amount												5,366
Accrued interest \| ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Amount												2,120
Accrued interest \| ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Amount												1,320
Accrued interest \| ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Amount												2,120
Accrued interest \| Noteholder
Debt Conversion, Converted Instrument, Amount												$ 19,868

XML 58 R47.htm IDEA: XBRL DOCUMENT

Note 9 - Derivative Liability (Details)	6 Months Ended
Note 9 - Derivative Liability (Details)	Jun. 30, 2019	Jun. 30, 2018
Annual dividend yield	0.00%	0.00%
Maximum
Expected life (years)	1 year	1 year
Risk-free interest rate	2.52%	2.57%
Expected volatility	294.00%	293.00%
Minimum
Expected life (years)	9 months 11 days	9 months 7 days
Risk-free interest rate	2.44%	2.07%
Expected volatility	274.00%	257.00%

XML 59 R48.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable (Details Narratives) - USD ($)	6 Months Ended
Note 10 - Note Payable (Details Narratives) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Disclosure Text Block [Abstract]
Notes payable from discontinued operations	$ 445,593		$ 52,500
Proceeds from notes payable	$ 393,093	$ 0
Interest rate	6.00%

XML 60 R49.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions (Details Narrative) - USD ($)						1 Months Ended					6 Months Ended
	Jan. 03, 2019	Aug. 13, 2018	May 03, 2018	Mar. 06, 2018	Jan. 10, 2018	Mar. 29, 2019	Feb. 15, 2019	Sep. 17, 2018	Jun. 25, 2018	Mar. 30, 2017	Jun. 30, 2019	Dec. 31, 2018
Common stock, shares authorized											800,000,000	800,000,000
ConvertibleNoteTwelveMember
Debt Conversion, Converted Instrument, Amount	$ 38,000
ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Shares Issued											25,674,344
ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Shares Issued											35,446,300
ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Shares Issued											48,693,873
ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Shares Issued											26,247,619
ConvertibleNoteThirteenMember
Debt Conversion, Converted Instrument, Amount							$ 38,000
ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Shares Issued											31,762,500
ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Shares Issued											14,859,260
ConvertibleNoteFifteenMember
Debt Conversion, Converted Instrument, Amount						$ 38,000
ConvertibleNoteFourteenMember
Debt Conversion, Converted Instrument, Amount						$ 38,000
Noteholder
Debt Conversion, Converted Instrument, Shares Issued											182,683,896
Principal \| ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Amount			$ 83,500								$ 53,957
Principal \| ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Amount				$ 126,000							60,000
Principal \| ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Amount					$ 240,000						71,732
Principal \| ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Amount		$ 53,000									53,000
Principal \| ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Amount								$ 33,000			33,000
Principal \| ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Amount									$ 53,000		38,000
Principal \| 8% Convertible Note
Debt Conversion, Converted Instrument, Amount										$ 75,000
Principal \| Noteholder
Debt Conversion, Converted Instrument, Amount											326,189
Accrued interest \| ConvertibleNoteEightMember
Debt Conversion, Converted Instrument, Amount											4,600
Accrued interest \| ConvertibleNoteSevenMember
Debt Conversion, Converted Instrument, Amount											4,342
Accrued interest \| ConvertibleNoteFiveMember
Debt Conversion, Converted Instrument, Amount											5,366
Accrued interest \| ConvertibleNoteTenMember
Debt Conversion, Converted Instrument, Amount											2,120
Accrued interest \| ConvertibleNoteElevenMember
Debt Conversion, Converted Instrument, Amount											1,320
Accrued interest \| ConvertibleNoteNineMember
Debt Conversion, Converted Instrument, Amount											2,120
Accrued interest \| Noteholder
Debt Conversion, Converted Instrument, Amount											$ 19,868

XML 61 R50.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
FDIC	$ 250,000
Second Customers [Member] \| Sales [Member]
Concentration percentage	16.00%	23.00%
One Customer [Member] \| Accounts Receivable [Member]
Concentration percentage	96.00%	100.00%
First Customers [Member] \| Sales [Member]
Concentration percentage	22.00%	32.00%
Third Customer [Member] \| Sales [Member]
Concentration percentage		22.00%
Fourth Customer [Member] \| Sales [Member]
Concentration percentage		10.00%

XML 62 R51.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions (Details Narratives) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Amounts due to related parties	$ 128,476	$ 145,367

XML 63 R52.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments and Contingencies (Details Narratives) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disclosure Text Block [Abstract]
Rent expense	$ 15,262	$ 14,235
Term	3 years
Base Salary	$ 75,000

XML 64 R53.htm IDEA: XBRL DOCUMENT

Note 16- Subsequent Events (Details Narrative)

Aug. 09, 2019

Subsequent Event [Member] | Clinigence Holdings

Merger Description

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 152 269 1 false 50 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://igambit.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://igambit.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Organization and Basis of Presentation Sheet http://igambit.com/role/Note1-OrganizationAndBasisOfPresentation Note 1 - Organization and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Going Concern Sheet http://igambit.com/role/Note3-GoingConcern Note 3 - Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Property and Equipment Sheet http://igambit.com/role/Note4-PropertyAndEquipment Note 4 - Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Intangible Assets Sheet http://igambit.com/role/Note5-IntangibleAssets Note 5 - Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Earnings (Loss) Per Common Share Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShare Note 6 - Earnings (Loss) Per Common Share Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Stock Based Compensation Sheet http://igambit.com/role/Note7-StockBasedCompensation Note 7 - Stock Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Convertible Debt Sheet http://igambit.com/role/Note8-ConvertibleDebt Note 8 - Convertible Debt Notes 14 false false R15.htm 00000015 - Disclosure - Note 9 - Derivative Liability Sheet http://igambit.com/role/Note9-DerivativeLiability Note 9 - Derivative Liability Notes 15 false false R16.htm 00000016 - Disclosure - Note 10 - Note Payable Sheet http://igambit.com/role/Note10-NotePayable Note 10 - Note Payable Notes 16 false false R17.htm 00000017 - Disclosure - Note 11 - Stock Transactions Sheet http://igambit.com/role/Note11-StockTransactions Note 11 - Stock Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Note 12 - Income Taxes Sheet http://igambit.com/role/Note12-IncomeTaxes Note 12 - Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - Note 13 - Concentrations and Credit Risk Sheet http://igambit.com/role/Note13-ConcentrationsAndCreditRisk Note 13 - Concentrations and Credit Risk Notes 19 false false R20.htm 00000020 - Disclosure - Note 14 - Related Party Transactions Sheet http://igambit.com/role/Note14-RelatedPartyTransactions Note 14 - Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Note 15 - Commitments and Contingencies Sheet http://igambit.com/role/Note15-CommitmentsAndContingencies Note 15 - Commitments and Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Note 16 - Subsequent Events Sheet http://igambit.com/role/Note16-SubsequentEvents Note 16 - Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies Note 2 - Summary of Significant Accounting Policies (Policies) Policies http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentTables Note 4 - Property and Equipment (Tables) Tables http://igambit.com/role/Note4-PropertyAndEquipment 25 false false R26.htm 00000026 - Disclosure - Note 5 - Intangible Assets (Tables) Sheet http://igambit.com/role/Note5-IntangibleAssetsTables Note 5 - Intangible Assets (Tables) Tables http://igambit.com/role/Note5-IntangibleAssets 26 false false R27.htm 00000027 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Tables) Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShareTables Note 6 - Earnings (Loss) Per Common Share (Tables) Tables http://igambit.com/role/Note6-EarningsLossPerCommonShare 27 false false R28.htm 00000028 - Disclosure - Note 7 - Stock Based Compensation (Tables) Sheet http://igambit.com/role/Note7-StockBasedCompensationTables Note 7 - Stock Based Compensation (Tables) Tables http://igambit.com/role/Note7-StockBasedCompensation 28 false false R29.htm 00000029 - Disclosure - Note 8 - Convertible Debt (Tables) Sheet http://igambit.com/role/Note8-ConvertibleDebtTables Note 8 - Convertible Debt (Tables) Tables http://igambit.com/role/Note8-ConvertibleDebt 29 false false R30.htm 00000030 - Disclosure - Note 9 - Derivative Liability (Tables) Sheet http://igambit.com/role/Note9-DerivativeLiabilityTables Note 9 - Derivative Liability (Tables) Tables http://igambit.com/role/Note9-DerivativeLiability 30 false false R31.htm 00000032 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails Note 2 - Summary of Significant Accounting Policies (Details) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 1) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails1 Note 2 - Summary of Significant Accounting Policies (Details 1) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 2) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails2 Note 2 - Summary of Significant Accounting Policies (Details 2) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000035 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narratives) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarratives Note 2 - Summary of Significant Accounting Policies (Details Narratives) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 00000036 - Disclosure - Note 3 - Going Concern (Details Narrative) Sheet http://igambit.com/role/Note3-GoingConcernDetailsNarrative Note 3 - Going Concern (Details Narrative) Details http://igambit.com/role/Note3-GoingConcern 35 false false R36.htm 00000037 - Disclosure - Note 4 - Property and Equipment (Details) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentDetails Note 4 - Property and Equipment (Details) Details http://igambit.com/role/Note4-PropertyAndEquipmentTables 36 false false R37.htm 00000038 - Disclosure - Note 4 - Property and Equipment (Details Narrative) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentDetailsNarrative Note 4 - Property and Equipment (Details Narrative) Details http://igambit.com/role/Note4-PropertyAndEquipmentTables 37 false false R38.htm 00000039 - Disclosure - Note 5 - Intangible Assets (Details) Sheet http://igambit.com/role/Note5-IntangibleAssetsDetails Note 5 - Intangible Assets (Details) Details http://igambit.com/role/Note5-IntangibleAssetsTables 38 false false R39.htm 00000040 - Disclosure - Note 5 - Intangible Assets (Details Narrative) Sheet http://igambit.com/role/Note5-IntangibleAssetsDetailsNarrative Note 5 - Intangible Assets (Details Narrative) Details http://igambit.com/role/Note5-IntangibleAssetsTables 39 false false R40.htm 00000041 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Details) Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShareDetails Note 6 - Earnings (Loss) Per Common Share (Details) Details http://igambit.com/role/Note6-EarningsLossPerCommonShareTables 40 false false R41.htm 00000042 - Disclosure - Note 7 - Stock Based Compensation (Details) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails Note 7 - Stock Based Compensation (Details) Details http://igambit.com/role/Note7-StockBasedCompensationTables 41 false false R42.htm 00000043 - Disclosure - Note 7 - Stock Based Compensation (Details 1) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails1 Note 7 - Stock Based Compensation (Details 1) Details http://igambit.com/role/Note7-StockBasedCompensationTables 42 false false R43.htm 00000044 - Disclosure - Note 7 - Stock Based Compensation (Details 2) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails2 Note 7 - Stock Based Compensation (Details 2) Details http://igambit.com/role/Note7-StockBasedCompensationTables 43 false false R44.htm 00000045 - Disclosure - Note 7 - Stock Based Compensation (Details 3) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails3 Note 7 - Stock Based Compensation (Details 3) Details http://igambit.com/role/Note7-StockBasedCompensationTables 44 false false R45.htm 00000046 - Disclosure - Note 8 - Convertible Debt (Details) Sheet http://igambit.com/role/Note8-ConvertibleDebtDetails Note 8 - Convertible Debt (Details) Details http://igambit.com/role/Note8-ConvertibleDebtTables 45 false false R46.htm 00000047 - Disclosure - Note 8 - Convertible Debt (Details Narrative) Sheet http://igambit.com/role/Note8-ConvertibleDebtDetailsNarrative Note 8 - Convertible Debt (Details Narrative) Details http://igambit.com/role/Note8-ConvertibleDebtTables 46 false false R47.htm 00000048 - Disclosure - Note 9 - Derivative Liability (Details) Sheet http://igambit.com/role/Note9-DerivativeLiabilityDetails Note 9 - Derivative Liability (Details) Details http://igambit.com/role/Note9-DerivativeLiabilityTables 47 false false R48.htm 00000049 - Disclosure - Note 10 - Note Payable (Details Narratives) Sheet http://igambit.com/role/Note10-NotePayableDetailsNarratives Note 10 - Note Payable (Details Narratives) Details http://igambit.com/role/Note10-NotePayable 48 false false R49.htm 00000050 - Disclosure - Note 11 - Stock Transactions (Details Narrative) Sheet http://igambit.com/role/Note11-StockTransactionsDetailsNarrative Note 11 - Stock Transactions (Details Narrative) Details http://igambit.com/role/Note11-StockTransactions 49 false false R50.htm 00000051 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) Sheet http://igambit.com/role/Note13-ConcentrationsAndCreditRiskDetailsNarrative Note 13 - Concentrations and Credit Risk (Details Narrative) Details http://igambit.com/role/Note13-ConcentrationsAndCreditRisk 50 false false R51.htm 00000052 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) Sheet http://igambit.com/role/Note14-RelatedPartyTransactionsDetailsNarratives Note 14 - Related Party Transactions (Details Narratives) Details http://igambit.com/role/Note14-RelatedPartyTransactions 51 false false R52.htm 00000053 - Disclosure - Note 15 - Commitments and Contingencies (Details Narratives) Sheet http://igambit.com/role/Note15-CommitmentsAndContingenciesDetailsNarratives Note 15 - Commitments and Contingencies (Details Narratives) Details http://igambit.com/role/Note15-CommitmentsAndContingencies 52 false false R53.htm 00000054 - Disclosure - Note 16- Subsequent Events (Details Narrative) Sheet http://igambit.com/role/Note16-SubsequentEventsDetailsNarrative Note 16- Subsequent Events (Details Narrative) Details 53 false false All Reports Book All Reports igmb-20190630.xml igmb-20190630.xsd igmb-20190630_cal.xml igmb-20190630_def.xml igmb-20190630_lab.xml igmb-20190630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 70 0001607062-19-000346-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-19-000346-xbrl.zip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end